MeiraGTx (MGTX) Projected to Post Quarterly Earnings on Thursday

MeiraGTx (NASDAQ:MGTX) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.46) per share and revenue of $6.95 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 20, 2026 at 12:30 PM ET.

MeiraGTx (NASDAQ:MGTX) last posted its earnings results on Thursday, August 13th. The company reported $1.71 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $2.17. MeiraGTx had a return on equity of 283.85% and a net margin of 19.87%. The firm had revenue of $321.43 million during the quarter, compared to analyst estimates of $0.70 million. On average, analysts expect MeiraGTx to post $0.30 EPS for the current fiscal year and ($2.01) EPS for the next fiscal year.

MeiraGTx Trading Up 1.4%

Shares of MGTX stock opened at $9.62 on Wednesday. MeiraGTx has a 12 month low of $6.62 and a 12 month high of $15.35. The company has a quick ratio of 3.76, a current ratio of 3.76 and a debt-to-equity ratio of 0.46. The business’s 50 day moving average is $11.00 and its two-hundred day moving average is $10.35. The company has a market cap of $923.90 million, a PE ratio of 13.55 and a beta of 1.09.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MGTX. The Goldman Sachs Group assumed coverage on shares of MeiraGTx in a report on Thursday, September 24th. They set a “neutral” rating and a $16.00 price objective for the company. Wall Street Zen upgraded shares of MeiraGTx from a “hold” rating to a “buy” rating in a research note on Saturday, October 24th. Weiss Ratings upgraded shares of MeiraGTx from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Zacks Research downgraded shares of MeiraGTx from a “strong-buy” rating to a “hold” rating in a report on Friday, September 11th. Finally, Royal Bank Of Canada boosted their target price on shares of MeiraGTx from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Friday, August 14th. Five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, MeiraGTx has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Insiders Place Their Bets

In related news, CEO Alexandria Forbes sold 62,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $13.86, for a total value of $859,320.00. Following the completion of the transaction, the chief executive officer directly owned 1,325,695 shares in the company, valued at approximately $18,374,132.70. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Naylor sold 27,659 shares of the company’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $10.64, for a total value of $294,291.76. Following the completion of the transaction, the insider owned 613,187 shares of the company’s stock, valued at $6,524,309.68. The trade was a 4.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 145,659 shares of company stock worth $1,710,812 in the last ninety days. Insiders own 7.40% of the company’s stock.

About MeiraGTx

MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.